MediPharm Labs Corp., a pharmaceutical company specializing in cannabinoid products, will announce its financial results for Q3 2026 on November 12 before market open. The company will hold a conference call and webcast at 10:00 a.m. Eastern time to discuss the results. MediPharm Labs operates globally with certifications like GMP and has expanded through acquisitions, including VIVO Cannabis Inc. This earnings report will provide insights into the company's recent performance and strategic progress.
MediPharm Labs' upcoming Q3 2026 financial results provide context for health sector activity on Pluang as of Nov 07, 2026 06:21 WIB: Among 150 priced US health stocks, 85 rose and 65 fell. Notably, FLNA dropped 19.26% to USD 0.47 with a typical hold time of 39 days, while XRAY and BKD fell 17.37% and 16.47% to USD 8.80 and USD 9.03 respectively, with XRAY held longer at 74 days and BKD much shorter at 11 days. Pluang order activity showed XRAY and BKD had 100% buy interest, contrasting FLNA's 42% sell activity.
Arcutis Biotherapeutics awarded 58,500 restricted stock units and options for 17,000 shares to six new employees as an inducement to join the company. The grants, approved under Nasdaq Listing Rule 5635(c)(4), vest over four years with specific sched...
The music duo for KING + COUNTRY released the Drummer Boy (Original Motion Picture Soundtrack) to coincide with the nationwide launch of their Christmas film DRUMMER BOY. The soundtrack features original songs by Joel and Luke Smallbone, reimagined C...
HMG Strategy is holding its first Tennessee C-Level Technology Leadership Summit on November 13 at W Nashville, bringing together CIOs, CISOs, CTOs, and senior tech executives from across Tennessee and the Mid-South. The summit will focus on AI, cybe...
Researcher Derik Kauffman revealed that Apple's iOS keyboard uses a secret 'gray list' of over 100,000 words and phrases that it blocks from autocomplete and swipe-typing suggestions. The list includes vulgar, offensive, drug-related, and politically...
Calumet reported a strong Q3 performance, surpassing analyst expectations with an EPS of $2.91 versus the estimated $1.63, and EBITDA of $347 million compared to the expected $269 million. The Specialty Products segment benefited from limited global ...
